{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:46:04Z","timestamp":1767649564671},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T00:00:00Z","timestamp":1098748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1007\/s10067-004-0944-1","type":"journal-article","created":{"date-parts":[[2004,10,25]],"date-time":"2004-10-25T10:57:29Z","timestamp":1098701849000},"page":"64-66","source":"Crossref","is-referenced-by-count":30,"title":["Transverse myelitis in a patient with Behcet\u2019s disease: favorable outcome with a combination of interferon-\u03b1"],"prefix":"10.1007","volume":"24","author":[{"given":"Meral","family":"\u00c7alg\u00fcneri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Mesut","family":"Onat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Akif","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"\u00d6z\u00e7akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"Ureten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Akdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130hsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,10,26]]},"reference":[{"key":"944_CR1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tasci B, The Neuro-Beh\u00e7et Study Group (1999) Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. Brain 122:2171\u20132181","journal-title":"Brain"},{"key":"944_CR2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3349\/ymj.1997.38.6.423","volume":"38","author":"Gurler","year":"1997","unstructured":"Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Beh\u00e7et\u2019s disease: an analysis of 2147 patients. Yonsei Med J 38:423\u2013427","journal-title":"Yonsei Med J"},{"key":"944_CR3","doi-asserted-by":"crossref","unstructured":"Assaad-Khalil S, Abou-Seif M, Abou-Seif S, El-Sewy F, El-Sewy M (1993) Neurologic involvement in Beh\u00e7et\u2019s disease: clinical, genetic and computed tomographic study. In: Wechsler B, Godeau P (eds) Beh\u00e7et\u2019s disease. Excerpta Medica International Congress Series, Amsterdam, pp 409\u2013414","DOI":"10.1016\/S0248-8663(05)82279-9"},{"key":"944_CR4","first-page":"499","volume":"59","author":"Transverse","year":"2002","unstructured":"Transverse Myelitis Consortium Working Group (2002) Proposed diagnostic criteria and nosology of acute transverse myelitis Neurology 59:499\u2013505","journal-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis Neurology"},{"key":"944_CR5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Beh\u00e7et\u2019s syndrome. Brain 122:2183\u20132194","journal-title":"Brain"},{"key":"944_CR6","first-page":"77s","volume":"27","author":"Ben","year":"2002","unstructured":"Ben Taarit C, Turki S, Ben Maiz H (2002) Neurological manifestations in Behcet\u2019s disease. Forty observations in a cohort of 300 patients J Mal Vasc 27:77s\u201381s","journal-title":"Forty observations in a cohort of 300 patients J Mal Vasc"},{"key":"944_CR7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.sc.3101190","volume":"39","author":"Kalita","year":"2001","unstructured":"Kalita J, Misra UK (2001) Is methyl prednisolone useful in acute transverse myelitis? Spinal Cord 39:471\u2013476","journal-title":"Spinal Cord"},{"key":"944_CR8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archneur.58.5.815","volume":"58","author":"Williams","year":"2001","unstructured":"Williams CS, Butler E, Roman GC (2001) Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58:815\u2013819","journal-title":"Arch Neurol"},{"key":"944_CR9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet\u2019s disease\u2014an update. Semin Arthritis Rheum 30:299\u2013312","journal-title":"Semin Arthritis Rheum"},{"key":"944_CR10","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"Zouboulis","year":"1998","unstructured":"Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 134:1010\u20131016","journal-title":"Arch Dermatol"},{"key":"944_CR11","doi-asserted-by":"crossref","unstructured":"Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G (1997) Interferon alpha for ocular Behcet\u2019s disease Acta Ophthalmol Scand 75:720\u2013722","DOI":"10.1111\/j.1600-0420.1997.tb00638.x"},{"key":"944_CR12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"K\u00f6tter","year":"1998","unstructured":"K\u00f6tter I, Eckstein AK, St\u00fcbiger N, Zierhut M (1998) Treatment of ocular symptoms of Behcet\u2019s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488\u2013494","journal-title":"Br J Ophthalmol"},{"key":"944_CR13","first-page":"1938","volume":"25","author":"O\u2019Duffy","year":"1998","unstructured":"O\u2019Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, Weyand C, Matteson E (1998) Interferon-alpha treatment of Behcet\u2019s disease. J Rheumatol 25:1938\u20131944","journal-title":"J Rheumatol"},{"key":"944_CR14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","volume":"243","author":"Georgiou","year":"1998","unstructured":"Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (1998) Efficacy and safety of systemic recombinant interferon-alpha in Behcet\u2019s disease. J Intern Med 243:367\u2013372","journal-title":"J Intern Med"},{"key":"944_CR15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","volume":"192","author":"Azizlerli","year":"1996","unstructured":"Azizlerli G, Sarica R, Kose A, Ovul C, Kavala M, Kayabali M, Erkan F, Kural Z (1996) Interferon alfa-2a in the treatment of Behcet\u2019s disease. Dermatology 192:239\u2013241","journal-title":"Dermatology"},{"key":"944_CR16","first-page":"1098","volume":"21","author":"Hamuryudan","year":"1994","unstructured":"Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Direskeneli H, Akoglu T, Yazici H (1994) Systemic interferon alpha 2b treatment in Behcet\u2019s syndrome. J Rheumatol 21:1098\u20131100","journal-title":"J Rheumatol"},{"key":"944_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","volume":"31","author":"Alpsoy","year":"1994","unstructured":"Alpsoy E, Yilmaz E, Basaran E (1994) Interferon therapy for Behcet\u2019s disease. J Am Acad Dermatol 31:617\u2013619","journal-title":"J Am Acad Dermatol"},{"key":"944_CR18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","volume":"62","author":"\u00c7alg\u00fcneri","year":"2003","unstructured":"\u00c7alg\u00fcneri M, \u0150zt\u00fcrk MA, Ertenli I, Kiraz S, Apra\u015f S, \u0150zbalkan Z (2003) Effects of interferon alpha treatment on the clinical course of refractory Beh\u00e7et\u2019s disease. Ann Rheum Dis 62:492\u2013493","journal-title":"Ann Rheum Dis"},{"key":"944_CR19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archneur.1996.00550070133022","volume":"53","author":"Akman-Demir","year":"1996","unstructured":"Akman-Demir G, Baykan-Kurt B, Serdaroglu P, G\u00fcrvit H, Yurdakul S, Yazici H, Bahar S, Aktin E (1996) Seven-year follow-up neurological involvement in Beh\u00e7et syndrome. Arch Neurol 53:691\u2013694","journal-title":"Arch Neurol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-0944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-004-0944-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-0944-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T13:06:55Z","timestamp":1585919215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-004-0944-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,26]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s10067-004-0944-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,26]]}}}